Advances in Biomarkers

1. EXECUTIVE SUMMARY

Macroscopic View of Biomarkers

• Go Biological with a Biomarker
• Types of Biomarkers
• Omics to Know-Omics Now

Scope and Methodology

• Scope and Segmentation of the Research Service
• Research Methodology

2. BIOMARKERS IN DRUG DISCOVERY

The Biomarker Method in Drug Discovery and Development

• Biomarkers May Relieve the Drug Discovery Bottleneck
• See Path to a Biomarker

Noteworthy Innovations

• Biomarker Serves as a Green Signal for a Small Molecule Drug and a Red Alert for Another
• Stack of Biomarkers Aid in Understanding Drug Toxicity
• Proteins Find it Difficult to Remain Undetected
• A Clear Vision and View for Metabolomics

Case Studies of Targeted Diagnostics for Targeted Therapeutics

• Diagnostic as a Companion to Therapeutic
• Wealth of Research on Anti-EGFR Therapy
• HIV Takes Diversion and Tricks the Drug
• Companion Diagnostics Make a Footprint

3. BIOMARKERS IN CLINICAL DIAGNOSTICS

The Biomarker Role in Clinical Diagnostics

• Better Diagnostics is Equal to Better Treatment
• Noteworthy Innovations in Oncology
• Noteworthy Innovation in Nononcology Areas

4. STRATEGIC EVALUATION OF THE BIOMARKER INDUSTRY

Application Trend Analysis

• Biomarkers Research Direction
• Biomarkers Promise to Deliver Sooner in Oncology

AHP--Prioritization of Biomarker Technologies

• Definition of Criteria
• AHP Process and Computation for Goal Node and Level 0 Criteria
• AHP Process and Computation for Goal Node and Level 1 Criteria
• Final Priorities and Analyst Insights

Force Field Analysis

• Growth Drivers and Growth Inhibitors
• Strategies for Change

5. STRATEGIC EVALUATION OF PATENTS AND KEY CONTACTS

Strategic Evaluation of Patents

• World Biomarker IP Portfolio--Drug Discovery
• Key Patents in Oncology--Diagnostics--Pertaining to Developments in Chapter 3.1
• Key Patents in Nononcology Areas--Diagnostics--Pertaining to Developments in Chapter 3.1

Key Contacts and Appendix

• Key Contacts
• Appendix

6. DECISION SUPPORT DATABASE

Database Tables

• Government Investment in Biotechnology--World (2002 to 2012)
• Percent Government R&D Investment in Biotechnology--World (2002 to 2012)
• Global Pharmaceutical R&D Expenditure (2002 to 2012)
• Global Percentage Pharmaceutical R&D Expenditure (2002 to 2012)